Abstract: Menopausal syndrome has a high incidence rate and significantly impacts women’s physical and mental health. Its exact pathogenesis remains unclear, but it is generally believed that hormonal changes during menopause are the primary cause of multisystem symptoms and systemic discomfort. Currently, hormone replacement therapy （HRT） is the main treatment for menopausal syndrome； however, HRT is not suitable for all menopausal patients. Recent studies have shown that HRT may increase the risk of coronary atherosclerotic heart disease, stroke, and breast cancer. Stellate ganglion block （SGB）, by modulating the sympathetic neural network, exerts inhibitory effects on excessive stress responses, anti-inflammatory and analgesic actions, and promotes neural function recovery, making it widely applicable in pain treatment and related fields. With the progressive advancement of research on SGB applications, increasing evidence suggests that SGB plays an important role in the treatment of menopausal syndrome. This article reviews the epidemiology, pathogenesis, diagnosis and treatment methods of menopausal syndrome, with a particular focus on the potential therapeutic role of SGB, which aims to provide new insights for research on menopausal syndrome treatment.